February 12, 2025 11:27 AM ESTUpdated 12:49 PM

AnaptysBio gets a mid-stage win for PD-1 drug in rheumatoid arthritis

Max Gelman

Senior Editor

AnaptysBio trumpeted a Phase 2b success in rheumatoid arthritis Wednesday morning after a similar program from Eli Lilly was discontinued late last year.

Anaptys’ program …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AnaptysBio gets a mid-stage win for PD-1 drug in rheumatoid arthritis

Max Gelman

Senior Editor

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

RFK Jr. convened roundtable around ways to reduce stem cell regulation

Boston Pharma, building off MASH momentum, mulls an IPO ahead of Phase 3 trial

Sutro slashes workforce in half, changes CEO and closes factory

Pfizer terminates an early-stage STING agonist trial

'It’s the law’: Dr. Oz says he would defend Medicare drug price negotiations

Obesity drug development—still room to grow

Anap­tys­Bio gets a mid-stage win for PD-1 drug in rheuma­toid arthri­tis

Senior Editor

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

AnaptysBio gets a mid-stage win for PD-1 drug in rheumatoid arthritis